The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Real-world long-term outcomes of patients with LBCL treated with axi-cel
Saurabh Dahiya, MD, University of Maryland School of Medicine, Baltimore, MD, presents data from a study evaluating the real-world long-term outcomes of patients with large B-cell lymphoma (LBCL) treated with standard of care (SOC) axicabtagene ciloleucel (axi-cel). After a median follow-up of 32 months, the study reported an overall survival (OS) and progression-free survival (PFS) at three years of 52% and 47% respectively, which is comparable to the results shown in the registrational ZUMA-1 study (NCT02348216). This study also found that a significant number of patients developed prolonged cytopenia (10%) and secondary malignant neoplasms (7%) after CAR-T therapy. Further investigation is required to better understand these long-term side effects. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
